Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.

On page 2152, in the second paragraph under “Discussion,” the investigators “observed better survival in gilteritinib-arm DNMT3A/NPM1 comutated patients,” not “c-mutated patients.”

https://doi.org/10.1182/bloodadvances.2022009077

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.